RKRanjith Kumar Ravi Kumar

Ranjith Kumar Ravi Kumar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ranjith Kumar Ravi Kumar has a total of 68 co-authors. Here are the top co-authors by number of shared publications:

  • J. Jayamuthunagai

    Centre for Biotechnology, Anna University, Chennai 600025, Tamilnadu, India

    4 shared publications
  • M. Chakravarthy

    Vel Tech High Tech Dr. Rangarajan Dr. Sakunthala Engineering College, Avadi, Chennai 600062, Tamilnadu, India

    4 shared publications
  • B. Bharathiraja

    3 shared publications
  • David Gómez-Varela

    Systems Biology of Pain, Division of Pharmacology & Toxicology, Department of Pharmaceutical Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria

    3 shared publications
  • Doriane Aguanno

    Chair of Nutrition and Immunology, Technical University of Munich, Freising, Germany

    3 shared publications
  • Feng Xian

    Systems Biology of Pain, Division of Pharmacology & Toxicology, Department of Pharmaceutical Sciences, University of Vienna, Austria

    3 shared publications

Latest Publications

  • Open Access

    Systematic evaluation of PASEF acquisition strategies in complex metaproteomes

    by Feng Xian, Goran Mitulovic, Ranjith Kumar Ravi Kumar, Lukas Uhrik, Elisabeth Urbauer, Doriane Aguanno, Dirk Haller, Manuela Schmidt, David Gomez-Varela

    Metaproteomics measures functional expression in complex microbial communities, but extreme sample complexity and dynamic range challenge acquisition strategies. Trapped ion mobility spectrometry with parallel accumulation–serial fragmentation (PASEF) has expanded into multiple acquisition modes, yet systematic evaluations in high-complexity metaproteomes remain limited. Here, we benchmark five PASEF modes—DDA-, DIA-, Slice-, Synchro-, and midia-PASEF—using a complex fecal peptide background spiked with defined bacterial references. Across three gradients and input levels, 540 LC–MS acquisitions are analyzed under matched conditions. Based on data-derived performance scores, DIA-based strategies outperform DDA-PASEF in peptide and protein coverage, particularly for low-abundance microbial features. DIA- and Slice-PASEF show strong quantitative reproducibility, reduced ratio compression, and consistent species-abundance scaling, while functional profiling reveals expanded annotation depth. When tested in a murine colonic injury model, the two highest-scoring methods, DIA- and Slice-PASEF, capture concordant host and microbial responses.


  • Comprehensive Sample Preparation Device for Multi-Omics Analysis

    by Ranjith Kumar Ravi Kumar

    Dispositif Complet de Préparation d'Echantillons pour l'Analyse Multi-Omique: Les trois dernières décennies ont vu l'apparition du concept de microbiome, qui désigne l'activité d'une communauté microbienne occupant un habitat bien défini (environnement ou animal hôte). L'étude des microbiomes vise à comprendre la contribution et l'impact de l'activité de la communauté microbienne. Contrairement à la méthode traditionnelle d'étude des espèces individuelles, l'accent est mis ici sur la communauté entière et la contribution des espèces individuelles au sein de cette communauté. Les trois grandes questions auxquelles les technologies disponibles permettent actuellement de répondre sont les suivantes : (i) quelles espèces sont là ? (ii) que peuvent-elles faire ? (iii) que font-elles ?Deux technologies analytiques sont couramment : la spectrométrie de masse pour les protéines et le séquençage de nouvelle génération pour les acides nucléiques. Avant d'utiliser ces technologies, le traitement pré-analytique des échantillons est une étape cruciale. Il existe des protocoles distincts pour la métaprotéomique, la métagénomique ou la métatranscriptomique afin de traiter les échantillons microbiens. Mais il n'existe toujours pas de système intégré permettant de préparer les échantillons pour ces différentes analyses.L'étude actuelle a permis de développer un protocole utilisant un dispositif microfluidique appelé ChipFilter pour effectuer une préparation automatisée et intégrée des échantillons pour la métaprotéomique et l'isolement séquentiel des acides nucléiques. Le ChipFilter a été développé précédemment dans le laboratoire pour effectuer la préparation d'échantillons pour la protéomique. Dans le présent travail, j'ai d'abord amélioré cette technologie pour effectuer la lyse de cellules bactériennes et fongiques, la purification des protéines, la protéolyse et l'isolement des acides nucléiques. Cinq différents protocoles permettent une préparation efficace des échantillons pour la métaprotéomique seule ou la méta-protéomique. Les flux de travail 1 à 3 ont permis la préparation d'échantillons avec lyse cellulaire, purification des protéines, protéolyse et récupération des peptides pour LC-MS/MS. Le tampon de lyse modifié dans le protocole 5 a permis une lyse cellulaire accrue des bactéries Gram +ve. Le protocole 4 a permis de récupérer les acides nucléiques après la récupération des peptides.Tous les protocoles ont été validés avec des mélanges standards - (1) un mélange de nombre égal de cellules de E. coli, S. cerevisiae et B. subtilis ; (2) vingt et une espèces de nombre disproportionné de cellules représentants le microbiome intestinal. Enfin, la validation du protocole métaprotéomique utilisant ChipFilter a été effectuée en utilisant le microbiome intestinal de la souris isolée à partir des fèces. La comparaison du protocole de ChipFilter avec les protocoles standards a montré une meilleure couverture du proteome avec le ChipFilter. Les peptides générés contenaient plus de sites de clivages manqués, ce qui a conduit à des séquences peptidiques plus longues et à une meilleure couverture des protéines. Nous avons identifié des protéines pour au moins 20 espèces parmi les 21 considérées. Le traitement du lysat du microbiome intestinal de la souris a conduit à l'identification de 650 protéines en moyenne à partir de quatre réplicats biologiques. En ce qui concerne les acides nucléiques extraits, leur stabilité structurelle, le mécanisme de leur rétention dans le ChipFilter et la validation par PCR ont été effectués.En conclusion, un protocole complet de préparation d'échantillons utilisant le ChipFilter a été réalisé pour la méta-protéogénomique. Ce protocole de préparation d’échantillon est automatisable, il peut être facilement intégré avec les étapes de collecte d'échantillons, et il permet d'effectuer des études multi omiques simultanément sur le même échantillon en permettant d'identifier un nombre élevé de peptides, ce qui le rend très prometteur pour des études de microbiome à haut débit.

  • Top Cited Papers
    Open Access

    Ultra-sensitive metaproteomics redefines the dark metaproteome, uncovering host-microbiome interactions and drug targets in intestinal diseases

    by Feng Xian, Malena Brenek, Christoph Krisp, Elisabeth Urbauer, Ranjith Kumar Ravi Kumar, Doriane Aguanno, Tharan Srikumar, Qixin Liu, Allison M. Barry, Bin Ma, et al.

    The functional characterization of host-gut microbiome interactions remains limited by the sensitivity of current metaproteomic approaches. Here, we present uMetaP, an ultra-sensitive workflow combining advanced LC-MS technologies with an FDR-validated de novo sequencing strategy, novoMP. uMetaP markedly expands functional coverage and improves the taxonomic detection limit of the gut dark metaproteome by 5000-fold, enabling precise detection and quantification of low-abundance microbial and host proteins. Applied to a mouse model of intestinal injury, uMetaP revealed host-microbiome functional networks underlying tissue damage, beyond genomic findings. Orthogonal validation using transcriptomic data from Crohn’s disease patients confirmed key host protein alterations. Furthermore, we introduce the concept of a druggable metaproteome, mapping functional targets within the host and microbiota. By redefining the sensitivity limits of metaproteomics, uMetaP provides a highly valuable framework for advancing microbiome research and developing therapeutic strategies for microbiome-related diseases.


  • Open Access

    A single microfluidic device for multi-omics analysis sample preparation

    by Ranjith Kumar Ravi Kumar, Iman Haddad, Massamba Mbacke Ndiaye, Martial Marbouty, Joelle Vinh, Yann Verdier

    Combining different “omics” approaches, such as genomics and proteomics, is necessary to generate a detailed and complete insight into microbiome comprehension. Proper sample collection and processing and accurate analytical methods are crucial in generating reliable data. We previously developed the ChipFilter device for proteomic analysis of microbial samples. We have shown that this device coupled to LC-MS/MS can successfully be used to identify microbial proteins. In the present work, we have developed our workflow to analyze concomitantly proteins and nucleic acids from the same sample. We performed lysis and proteolysis in the device using cultures of E. coli, B. subtilis , and S. cerevisiae . After peptide recovery for LC-MS/MS analysis, DNA from the same samples was recovered and successfully amplified by PCR for the 3 species. This workflow was further extended to a complex microbial mixture of known compositions. Protein analysis was carried out, enabling the identification of more than 5000 proteins. The recovered DNA was sequenced, performing comparable to DNA extracted with a commercial kit without proteolysis. Our results show that the ChipFilter device is suited to prepare samples for parallel proteomic and genomic analyses, which is particularly relevant in the case of low-abundant samples and drastically reduces sampling bias.

  • Open Access

    Ultra-sensitivity metaproteomics redefines the gut “dark metaproteome”, uncovering host-microbiome interactions and drug targets in intestinal inflammatory diseases

    by Feng Xian, Malena Brenek, Christoph Krisp, Doriane Aguanno, Elisabeth Urbauer, Tharan Srikumar, Ranjith Kumar Ravi Kumar, Qixin Liu, Allison M Barry, Bin Ma, et al.

    The gut microbiome is a complex ecosystem with significant inter-individual variability determined by hundreds of low-abundant species as revealed by genomic methods. Functional redundancy demands direct quantification of microbial biological functions to understand their influence on host physiology. This functional landscape remains unexplored due to limited sensitivity in metaproteomics methods. We present uMetaP, an ultra-sensitive metaproteomic solution combining advanced LC-MS technologies with a novel FDR- controlled de novo strategy. uMetaP improves the taxonomic detection limit of the gut "dark metaproteome" by 5,000-fold with exceptional quantification precision and accuracy. In a mouse model of colonic injury, uMetaP extended metagenomics findings and identified host functions and microbial metabolic networks linked to disease. We obtained orthogonal validation using transcriptomic data from biopsies of 204 Crohn’s patients and presented the concept of a "druggable metaproteome". Among the drug-protein interactions discovered are treatments for intestinal inflammatory diseases, showcasing uMetaP’s potential for disease diagnostics and data-driven drug repurposing strategies.


  • Open Access

    ChipFilter: Microfluidic Based Comprehensive Sample Preparation Methodology for Metaproteomics

    by Ranjith Kumar Ravi Kumar, Massamba Mbacke Ndiaye, Iman Haddad, Joelle Vinh, Yann Verdier

    Metaproteomic approach is an attractive way to describe a microbiome at the functional level, allowing the identification and quantification of proteins across a broad dynamic range as well as detection of post-translational modifications. However, it remains relatively underutilized, mainly due to technical challenges that should be addressed, including the complexity in extracting proteins from heterogenous microbial communities. Here, we show that a ChipFilter microfluidic device coupled to LC-MS/MS can successfully be used for identification of microbial proteins. Using cultures of E. coli, B. subtilis and S. cerevisiae , we have shown that it is possible to directly lyse the cells and digest the proteins in the ChipFilter to allow higher number of proteins and peptides identification than standard protocols, even at low cell density. The peptides produced are overall longer after ChipFilter digestion but show no change in their degree of hydrophobicity. Analysis of a more complex mixture of 17 species from the gut microbiome showed that the ChipFilter preparation was able to identify and estimate the amount of 16 of these species. These results show that ChipFilter can be used for the proteomic study of microbiomes, in particular in the case of low volume or low cell density.

  • Open Access

    Invariant Differential Expression Analysis Reveals Mechanism of Cancer Resistance to Cell Cycle Inhibitors

    by Amit Chatterjee, Sonalisa Pandey, Ravikanth Danda, R Ranjith Kumar, S Maheswari, Vikas Khetan, Pukhraj Rishi, S Ramaprabhu, Sailaja V Elchuri, Debashis Sahoo

    Retinoblastoma (RB) is a good model to study drug resistance to cell-cycle inhibitors because it is driven by mutations in the core components of cell-cycle, i.e, Rb gene. However, there is limited gene expression dataset in RB which has major reproducibility issues. We have developed invariant differential expression analysis (iDEA) that improves the state of the art in differential expression analysis (DEA). iDEA uses strong Boolean implication relationships in a large diverse human dataset GSE119087 (n = 25,955) to filter the noisy differentially expressed genes (DEGs). iDEA was applied to RB datasets and a gene signature was computed that led to prediction and mechanism of drug sensitivity. The prediction was confirmed using drugs-sensitive/resistant RB cell-lines and mouse xenograft models using CDC25 inhibitor NSC663284. iDEA improved reproducibility of differential expression across diverse retina/RB cohorts and RB cell-lines with different drug sensitivity (Y79/Weri vs NCC). Pathway analysis revealed WNT/β-catenin involved in distinguishing drug sensitivity to CDC25 inhibitor NSC663284. NSC663284 inhibited tumour cell proliferation in mouse xenograft model containing Y79 cells indicating novel therapeutic option in RB. Invariant differentially expressed genes (iDEGs) are robustly associated with outcome in diverse cancer datasets and supports for a fundamental mechanism of drug resistance.

  • Open Access

    Non-coding and Coding Transcriptional Profiles Are Significantly Altered in Pediatric Retinoblastoma Tumors

    by Swetha Rajasekaran, Lakshmi Dhevi Nagarajha Selvan, Kathleen Dotts, Ranjith Kumar, Pukhraj Rishi, Vikas Khetan, Madhoolika Bisht, Karthikeyan Sivaraman, Subrmanian Krishnakumar, Debashis Sahoo, et al.

    Retinoblastoma is a rare pediatric tumor of the retina, caused by the homozygous loss of the Retinoblastoma 1 (RB1) tumor suppressor gene. Previous microarray studies have identified changes in the expression profiles of coding genes; however, our understanding of how non-coding genes change in this tumor is absent. This is an important area of research, as in many adult malignancies, non-coding genes including LNC-RNAs are used as biomarkers to predict outcome and/or relapse. To establish a complete and in-depth RNA profile, of both coding and non-coding genes, in Retinoblastoma tumors, we conducted RNA-seq from a cohort of tumors and normal retina controls. This analysis identified widespread transcriptional changes in the levels of both coding and non-coding genes. Unexpectedly, we also found rare RNA fusion products resulting from genomic alterations, specific to Retinoblastoma tumor samples. We then determined whether these gene expression changes, of both coding and non-coding genes, were also found in a completely independent Retinoblastoma cohort. Using our dataset, we then profiled the potential effects of deregulated LNC-RNAs on the expression of neighboring genes, the entire genome, and on mRNAs that contain a putative area of homology. This analysis showed that most deregulated LNC-RNAs do not act locally to change the transcriptional environment, but potentially function to modulate genes at distant sites. From this analysis, we selected a strongly down-regulated LNC-RNA in Retinoblastoma, DRAIC, and found that restoring DRAIC RNA levels significantly slowed the growth of the Y79 Retinoblastoma cell line. Collectively, our work has generated the first non-coding RNA profile of Retinoblastoma tumors and has found that these tumors show widespread transcriptional deregulation.


  • Open Access

    Metabolite systems profiling identifies exploitable weaknesses in retinoblastoma

    by Swagatika Sahoo, Ranjith Kumar Ravi Kumar, Brandon Nicolay, Omkar Mohite, Karthikeyan Sivaraman, Vikas Khetan, Pukhraj Rishi, Suganeswari Ganesan, Krishnakumar Subramanyan, Karthik Raman, et al.

    Retinoblastoma (RB) is a childhood eye cancer. Currently, chemotherapy, local therapy, and enucleation are the main ways in which these tumors are managed. The present work is the first study that uses constraint‐based reconstruction and analysis approaches to identify and explain RB‐specific survival strategies, which are RB tumor specific. Importantly, our model‐specific secretion profile is also found in RB1‐depleted human retinal cells in vitro and suggests that novel biomarkers involved in lipid metabolism may be important. Finally, RB‐specific synthetic lethals have been predicted as lipid and nucleoside transport proteins that can aid in novel drug target development.


  • Biodiesel production from different algal oil using immobilized pure lipase and tailor made rPichia pastoris with Cal A and Cal B genes

    by B. Bharathiraja, R. Ranjith Kumar, R. PraveenKumar, M. Chakravarthy, D. Yogendran, J. Jayamuthunagai